Subscribe
Models
HUGO Series 🌟
Cell Line Models
Services
Preclinical Efficacy
Resources
About Us
NKG B2m KO Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
NKG B2m KO Mouse
Product Name
NKG B2m KO Mouse
Product ID
C001416
Strain Name
NOD.Cg-PrkdcscidIl2rgem1cyaB2mem1cya/Cya
Backgroud
NKG
Status
When using this mouse strain in a publication, please cite “NKG B2m KO Mouse (Catalog C001416) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Basic Information
Validation Data
Related Resource
Basic Information
Gene Name
B2m & Il2rg
Gene Alias
Ly-m11, beta2m, beta2-m, gc, p64, [g]c, CD132, gamma(c)
NCBI ID
Chromosome
Chr 2 (Mouse), Chr X (Mouse)
Datasheet
Strain Description
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
In the field of immunology research, there are differences between humans and mice in terms of physiology and immune systems, so research conducted directly on mice cannot fully reflect the human situation. By transplanting human peripheral blood mononuclear cells (PBMC) or human hematopoietic stem cells (HSC) into immunodeficient mice, the mouse’s immune system is partially or completely replaced by the human immune system, allowing for the simulation of human immune system function in vivo and providing an effective model for studying the human immune system. PBMC transplantation into NKG mice has the advantages of high immune reconstitution efficiency and fast speed. After 3 weeks of transplantation, the average proportion of human CD45+ cells in peripheral blood can reach about 50%. However, due to the mismatch between human immune cells and mouse MHC molecules, graft-versus-host disease (GvHD) occurs, where transplanted human immune cells (including T cells, B cells, and NK cells) attack mouse tissues, causing inflammation and tissue damage, ultimately leading to rapid death of the mouse. This results in a very limited experimental window.
The B2M gene encodes β2-microglobulin, a serum protein that exists on the surface of almost all nucleated cells in conjunction with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for the transport of MHC class I proteins to the cell surface. Studies have shown that knocking out the B2m gene in immunodeficient mice can lead to a lack of MHC class I molecule expression, thereby reducing graft-versus-host disease (GvHD) and extending the experimental window for PBMC immune reconstitution [1-2]. NKG B2m KO mice are constructed by knocking out the B2m gene on the background of NKG mice. Compared with NKG mice, NKG B2m KO mice have a significantly longer survival period after PBMC transplantation and can be used for long-term studies of PBMC immune system reconstitution.
Reference
Yaguchi T, Kobayashi A, Inozume T, Morii K, Nagumo H, Nishio H, Iwata T, Ka Y, Katano I, Ito R, Ito M, Kawakami Y. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 2018 Nov;15(11):953-962.
Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M. Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Front Oncol. 2021 Nov 18;11:784947.
Strain Strategy
Knockout of B2m gene in NKG mice by gene editing technology.
Application Area
Establishment of humanized immune system mouse model;
Research on graft-versus-host disease (GvHD);
Research on the immune system, hematopoietic system, and blood disease;
Cell line-derived xenograft (CDX) and drug screening and efficacy evaluation;
Patient-derived xenograft (PDX) and drug screening and efficacy evaluation.
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
